Alector, Inc.

Vigil Neuroscience’s TREM2 agonist iluzanebart failed in a Phase II study for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and deadly neurod

Having established itself as an immunology powerhouse , Sanofi is looking to use that expertise to become a key player in neurodegenerative diseases by acquiring Vigil Neuroscience and getting hold o

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

Another day, another Alzheimer’s failure. This time it is the turn of Alector, whose AbbVie-partnered anti-TREM2 antibody, AL002, failed in Phase II, and while this is not quite as big a catastrophe